Publications
Some information below relates to investigational products and/or uses for which safety and efficacy have not been established. There is no guarantee that pipeline products or investigational uses will receive approval from health authorities.
"Evaluation of tissue-engineered human acellular vessels as a Blalock–Taussig–Thomas shunt in a juvenile primate model"– 2023
Nash KM, Boe BA, Carrillo SA, et al. Evaluation of tissue-engineered human acellular vessels as a Blalock–Taussig–Thomas shunt in a juvenile primate model. JTCVS Open. 2023;15:433-445. doi:https://doi.org/10.1016/j.xjon.2023.05.018.
"Evaluation of vascular repair by tissue-engineered human acellular vessels or expanded polytetrafluoroethylene grafts in a porcine model of limb ischemia and reperfusion"– 2023
Kirkton RD, Watson JDB, Houston R, Prichard HL, Niklason LE, Rasmussen TE. Evaluation of vascular repair by tissue-engineered human acellular vessels or expanded polytetrafluoroethylene grafts in a porcine model of limb ischemia and reperfusion. The Journal of Trauma and Acute Care Surgery. 2023;95(2):234-241. doi:https://doi.org/10.1097/TA.0000000000003974.
"Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts"– 2023
Wang J, Blalock SKF, Levitan GS, Prichard HL, Niklason LE, Kirkton RD. Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts. JVS-Vascular Science. 2023;4:100120. doi:https://doi.org/10.1016/j.jvssci.2023.100120.
"Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine–Russia conflict"– 2023
Sokolov AN, Shaprynskyi VO, Oleh Skupyy, et al. Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine–Russia conflict. The Lancet regional health. 2023;29:100650-100650. doi:https://doi.org/10.1016/j.lanepe.2023.100650.
"Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass"– 2023
Gutowski P, Guziewicz M, Ilzecki M, et al. Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass. JVS-vascular science. 2023;4:100092. doi:https://doi.org/10.1016/j.jvssci.2022.11.001.
"Preliminary Experience With the Human Acellular Vessel: A Descriptive Case Series Detailing Early Use of a Bioengineered Blood Vessel for Arterial Repair"– 2022
Preliminary Experience With the Human Acellular Vessel: A Descriptive Case Series Detailing Early Use of a Bioengineered Blood Vessel for Arterial Repair Lauria, Alexis L. et al. Annals of Vascular Surgery,Volume 87, 100 – 112.
"Bioengineering Human Tissues and the Future of Vascular Replacement"– 2022
Naegeli KM, Kural MH, Li Y, Wang J, Hugentobler EA, Niklason LE. Bioengineering Human Tissues and the Future of Vascular Replacement. Circulation Research. 2022;131(1):109-126. doi:https://doi.org/10.1161/circresaha.121.319984.
"The Human Acellular Vessel for Vascular Reconstruction or Bypass A Novel Biologic Conduit for Vascular Bypass and Repair"– 2022
Lauria AL, Sen I, Rasmussen TE. The Human Acellular Vessel for Vascular Reconstruction or Bypass. JAMA Surgery. 2022;157(8):731. doi:https://doi.org/10.1001/jamasurg.2022.1214.
"Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access"– 2022
Jakimowicz T, Przywara S, Turek J, et al. Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access. EJVES Vascular Forum. 2022;54:58-63. doi:https://doi.org/10.1016/j.ejvsvf.2022.01.003.
"Surgical Management of an Infected External Iliac Artery Interposition Graft with a Bioengineered Human Acellular Vessel" – 2021
Guth C, Naslund T. Surgical management of an infected external iliac artery interposition graft with a bioengineered human acellular vessel. Journal of Vascular Surgery Cases, Innovations and Techniques. 2022;8(1):111-114. doi:https://doi.org/10.1016/j.jvscit.2021.10.002.
"Development of a Bioartificial Vascular Pancreas" – 2021
Han EX, Wang J, Kural M, et al. Development of a Bioartificial Vascular Pancreas. Journal of Tissue Engineering. 2021;12:204173142110277. doi:https://doi.org/10.1177/20417314211027714.
"Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-analysis" – 2020
Halbert RJ, Nicholson G, Nordyke RJ, Pilgrim A, Niklason L. Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-Analysis. Kidney360. 2020;1(12):1437-1446. doi:https://doi.org/10.34067/kid.0003502020.
"Arterial Reconstruction with Human Bioengineered Acellular Blood Vessels in Patients with Peripheral Arterial Disease" – 2020
Gutowski P, Gage SM, Guziewicz M, et al. Arterial reconstruction with human bioengineered acellular blood vessels in patients with peripheral arterial disease. Journal of Vascular Surgery. 2020;72(4):1247-1258. doi:https://doi.org/10.1016/j.jvs.2019.11.056.
"Bioengineered Human Blood Vessels" – 2020
Niklason LE, Lawson JH. Bioengineered human blood vessels. Science. 2020;370(6513). doi:https://doi.org/10.1126/science.aaw8682.
"Challenges and Novel Therapies for Vascular Access in Haemodialysis" – 2020
Lawson JH, Niklason LE, Roy-Chaudhury P. Challenges and novel therapies for vascular access in haemodialysis. Nature Reviews Nephrology. 2020;16(10):586-602. doi:https://doi.org/10.1038/s41581-020-0333-2.
"Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage 2012-2014" – 2020
Nephrol A, Bylsma L, Reichert H, et al. Original Report: Patient-Oriented, Translational Research Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014.; 2012. Accessed November 8, 2024. https://humacyte.com/wp-content/uploads/2024/08/Bylsma_AJN-2019_Clinical-outcomes-of-AV-in-HD-2012-2014.pdf.
"Bioengineered Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels after Human Implantation" – 2019
Kirkton R, Santiago-Maysonet M, Lawson J, et al. Bioengineered Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels after Human Implantation. Accessed November 8, 2024. https://humacyte.com/wp-content/uploads/2024/08/2019.-Kirkton-Sci.Trans_.Medicine-Bioengineeredhumcan-acellular-vessels-recellularize.pdf.
"Clinical Implementation of the Humacyte Human Acellular Vessel: Implications for Military and Civilian Trauma Care"– 2019
Morrison JJ, McMahon J, DuBose JJ, Scalea TM, Lawson JH, Rasmussen TE. Clinical implementation of the Humacyte human acellular vessel: Implications for military and civilian trauma care. Journal of Trauma and Acute Care Surgery. 2019;87(1S):S44-S47. doi:https://doi.org/10.1097/ ta.0000000000002350.
"Cost Attributable to Arteriovenous Fistulae And Arteriovenous Graft Placements in Hemodialysis Patients with Medicare Coverage"– 2019
Nephrol A, Nordyke R, Reichert H, et al. Novel Research Findings Costs Attributable to Arteriovenous Fistula and Arteriovenous Graft Placements in Hemodialysis Patients with Medicare Coverage.; 2019. Accessed November 8, 2024. https://humacyte.com/wp-content/uploads/2024/08/Nordyke_AJN2019_Costs-of-AVF-and-AVGs-in-Medicare.pdf.
"Susceptibility of EPTFE Vascular Grafts and Bioengineered Human Acellular Vessels to Infection"– 2018
Kirkton RD, Prichard HL, Santiago-Maysonet M, Niklason LE, Lawson JH, Dahl SLM. Susceptibility of ePTFE vascular grafts and bioengineered human acellular vessels to infection. Journal of Surgical Research. 2018;221:143-151. doi:https://doi.org/10.1016/j.jss.2017.08.035.
"Arteriovenous Fistulae for Hemodialysis: A Systematic Review and Meta-Anaylsis of Efficacy and Safety Outcomes"– 2017
Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH. Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes. European Journal of Vascular and Endovascular Surgery. 2017;54(4):513-522. doi:https://doi.org/10.1016/j.ejvs.2017.06.024.
"Bioengineered Hemodialysis Access Graft" – 2017
Gage SM, Lawson JH. Bioengineered hemodialysis access grafts. The Journal of Vascular Access. 2017;18(1_suppl):S56-S63. doi:https://doi.org/10.5301/jva.5000692.
"Bioengineered Human Acellular Vessels for Dialysis Access in Patients with End-Stage Renal Disease: Two Phase 2 Single-Arm Trials"– 2016
Lawson JH, Glickman MH, Ilzecki M, et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. The Lancet. 2016;387(10032):2026-2034. doi:https://doi.org/10.1016/s0140-6736(16)00557-2.
"An Early Study on the Mechanisms that Allow Tissue-Engineered Vascular Grafts to Resist Intimal Hyperplasia"– 2011
Prichard H, Manson R, Dibernardo L, et al. An Early Study on the Mechanisms that Allow Tissue Engineered Vascular Grafts to Resist Intimal Hyperplasia. J of Cardiovasc Trans Res. 2011;4:674-682. doi:https://doi.org/10.1007/sl2265-0ll-9306-y.
"Readily Available Tissue-Engineered Vascular Grafts"– 2011
Dahl SLM, Kypson AP, Lawson JH, et al. Readily Available Tissue-Engineered Vascular Grafts. Science Translational Medicine. 2011;3(68). doi:https://doi.org/10.1126/scitranslmed.3001426.